These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28866826)

  • 1. Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients.
    Pariente A; Mansiaux Y; Jarné A; Salvo F; Pageot C; Bezin J; Smith A; Bégaud B
    Eur J Clin Pharmacol; 2017 Dec; 73(12):1655-1663. PubMed ID: 28866826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
    Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A;
    Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
    Noh Y; Kang DR; Kim DJ; Lee KJ; Lee S; Shin S
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1338-1346. PubMed ID: 28771933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased incidence of gout in diabetic patients using pioglitazone.
    Niu SW; Chang KT; Lin HY; Kuo IC; Chang YH; Chen YH; Hung CC; Chiu YW; Hwang SJ
    Rheumatology (Oxford); 2018 Jan; 57(1):92-99. PubMed ID: 29040733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
    Karter AJ; Ahmed AT; Liu J; Moffet HH; Parker MM
    Diabet Med; 2005 Aug; 22(8):986-93. PubMed ID: 16026362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France.
    Arnaud M; Bezin J; Bégaud B; Pariente A; Salvo F
    Fundam Clin Pharmacol; 2017 Dec; 31(6):663-675. PubMed ID: 28575541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
    Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
    Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use.
    Romero V; Peyton C; Gray I; Hemal A; Terlecki R
    BMC Urol; 2014 Jan; 14():10. PubMed ID: 24461081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
    Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited impact of drug exposure misclassification from non-benefit thiazolidinedione drug use on mortality and hospitalizations from Saskatchewan, Canada: a cohort study.
    Gamble JM; Johnson JA; McAlister FA; Majumdar SR; Simpson SH; Eurich DT
    Clin Ther; 2015 Mar; 37(3):629-42. PubMed ID: 25596665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
    Chen X; Yang L; Zhai SD
    Chin Med J (Engl); 2012 Dec; 125(23):4301-6. PubMed ID: 23217404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.